The new recommendation aligns with the EU’s Beating Cancer Plan and responds to persistent inequalities driven by opportunistic PSA testing (“wild screening”): in the absence of organized programs, more educated or proactive men tend to get PSA tests, while others (including high-risk groups) may miss out. The gene discussed is KLK3; the disease is cancer.